Published in Br J Pharmacol on August 01, 1990
Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents. Br J Pharmacol (1991) 1.28
Intra-prefrontal 8-OH-DPAT and M100907 improve visuospatial attention and decrease impulsivity on the five-choice serial reaction time task in rats. Psychopharmacology (Berl) (2003) 1.28
Obsessive-compulsive disorder in schizophrenia: epidemiologic and biologic overlap. J Psychiatry Neurosci (1999) 1.17
Locomotor-activated neurons of the cat. I. Serotonergic innervation and co-localization of 5-HT7, 5-HT2A, and 5-HT1A receptors in the thoraco-lumbar spinal cord. J Neurophysiol (2009) 0.87
Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo. Br J Pharmacol (1992) 0.83
The effects of alpha 2-adrenoceptor antagonists on the inhibition of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced head shakes by 5-HT1A receptor agonists in the mouse. Br J Pharmacol (1993) 0.78
The PKC inhibitor, bisindolymaleimide, blocks DOI's attenuation of the effects of 8-OH-DPAT on female rat lordosis behavior. Behav Brain Res (2007) 0.77
Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology (Berl) (1993) 0.77
The stimulus effects of 8-OH-DPAT: evidence for a 5-HT2A receptor-mediated component. Pharmacol Biochem Behav (2007) 0.75
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology (1986) 5.83
Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci (1981) 3.71
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol (1979) 2.89
8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. Eur J Pharmacol (1983) 2.45
Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature (1988) 2.42
The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol (1984) 1.79
The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. Eur J Pharmacol (1984) 1.74
The effects of putative 5-hydroxytryptamine antagonists on the behaviour produced by administration of tranylcypromine and L-tryptophan or tranylcypromine and L-DOPA to rats. Br J Pharmacol (1978) 1.48
Functional correlates of serotonin 5-HT1 recognition sites. J Recept Res (1988) 1.48
An animal behavior model for studying central serotonergic synapses. Life Sci (1976) 1.47
A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors. Br J Pharmacol (1985) 1.43
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
Blockage of amphetamine induced motor stimulation and stereotypy in the adult rat following neonatal treatment with 6-hydroxydopamine. Brain Res (1973) 1.26
"Wet-dog" shake behaviour in the rat: a possible quantitative model of central 5-hydroxytryptamine activity. Neuropharmacology (1977) 1.24
Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol (1985) 1.21
Molecular pharmacology and biology of 5-HT1C receptors. Trends Pharmacol Sci (1988) 1.16
Determination of selective and nonselective compounds for the 5-HT 1A and 5-HT 1B receptor subtypes in rat frontal cortex. J Pharmacol Exp Ther (1984) 1.15
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
Facilitation of 8-OHDPAT-induced forepaw treading of rats by the 5-HT2 agonist DOI. Eur J Pharmacol (1989) 1.09
Selective interaction of novel anxiolytics with 5-hydroxytryptamine1A receptors. Biol Psychiatry (1985) 1.08
Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol (1988) 1.02
Correlations between different measures of antiserotonin activity of drugs. Study with neuroleptics and serotonin receptor blockers. Naunyn Schmiedebergs Arch Pharmacol (1982) 0.98
Behavioral evidence for supersensitivity following destruction of central serotonergic nerve terminals by 5,7-dihydroxytryptamine. J Pharmacol Exp Ther (1976) 0.98
Involvement of 5-HT2 receptors in the wet-dog shake behaviour induced by 5-hydroxytryptophan in the rat. Neuropharmacology (1983) 0.97
Detection and characterization of the serotonin 5-HT 1D receptor in rat and human brain. J Neurochem (1988) 0.95
Serotonergic mechanisms in the behavioral effects of buspirone and gepirone. Pharmacol Biochem Behav (1986) 0.92
Serotonin 5-HT1 receptors mediate inhibition of cyclic AMP production in neurons. Eur J Pharmacol (1986) 0.91
5-HT1 and 5-HT2 binding properties of derivatives of the hallucinogen 1-(2,5-dimethoxyphenyl)-2-aminopropane (2,5-DMA). Eur J Pharmacol (1984) 0.90
The head-twitch response to intraperitoneal injection of 5-hydroxytryptophan in the rat: antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. Neuropharmacology (1983) 0.88
Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378. Eur J Pharmacol (1990) 0.87
Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat. Eur J Pharmacol (1985) 0.87
Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rat. Psychopharmacology (Berl) (1985) 0.84
Head twitches induced by LSD and quipazine: similarities and differences. Neuropharmacology (1980) 0.83
Electrophysiological assessment of putative antagonists of 5-hydroxytryptamine receptors: a single-cell study in the rat dorsal raphe nucleus. Can J Physiol Pharmacol (1989) 0.81
A review of central 5-HT receptors and their function. Neuropharmacology (1999) 6.13
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
Catechol-o-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci (2004) 2.35
Cross infection control measures and the treatment of patients at risk of Creutzfeldt Jakob disease in UK general dental practice. Br Dent J (2001) 2.08
Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90
The role of breakfast in the treatment of obesity: a randomized clinical trial. Am J Clin Nutr (1992) 1.83
Misuse of temazepam. BMJ (1991) 1.82
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
Neurochemical and anatomical identification of fast- and slow-firing neurones in the rat dorsal raphe nucleus using juxtacellular labelling methods in vivo. Neuroscience (2003) 1.61
In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. J Neurochem (1983) 1.60
Differential involvement of serotonin and dopamine systems in cost-benefit decisions about delay or effort. Psychopharmacology (Berl) (2004) 1.58
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
An electrophysiological and neuroanatomical study of the medial prefrontal cortical projection to the midbrain raphe nuclei in the rat. Neuroscience (1998) 1.47
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
The effect of prolonged pneumoperitoneum on renal function in an animal model. J Am Coll Surg (1996) 1.41
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
A direct comparison of amphetamine-induced behaviours and regional brain dopamine release in the rat using intracerebral dialysis. Brain Res (1987) 1.36
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol (1989) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med (1978) 1.34
Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
Evidence for a role of GABA interneurones in the cortical modulation of midbrain 5-hydroxytryptamine neurones. Neuroscience (2001) 1.30
Confounding effects of anesthesia on functional activation in rodent brain: a study of halothane and alpha-chloralose anesthesia. Neuroimage (2005) 1.30
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry (1975) 1.28
Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol (1995) 1.26
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26
Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol (1979) 1.23
A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma. Br J Clin Pharmacol (1977) 1.17
The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer (1994) 1.15
A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine. J Auton Pharmacol (1983) 1.15
In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. Eur J Pharmacol (1988) 1.14
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13
Electrophysiological evidence for convergence of inputs from the medial prefrontal cortex and lateral habenula on single neurons in the dorsal raphe nucleus. Eur J Neurosci (2003) 1.13
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13
Widespread distribution of binding sites for the novel Ca2+-mobilizing messenger, nicotinic acid adenine dinucleotide phosphate, in the brain. J Biol Chem (2000) 1.12
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
Psittacosis masquerading as rheumatic fever. Br Med J (1978) 1.12
Effect of a tyrosine-free amino acid mixture on regional brain catecholamine synthesis and release. Psychopharmacology (Berl) (1999) 1.12
The relationship between plasma catecholamines and severity of injury in man. J Trauma (1984) 1.11
Functional mapping of dorsal and median raphe 5-hydroxytryptamine pathways in forebrain of the rat using microdialysis. J Neurochem (1997) 1.11
Abnormal regulation of adenosine 3',5'-monophosphate and corticosterone formation in an adrenocortical carcinoma. J Clin Invest (1969) 1.11
Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11
Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10
Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat. Br J Pharmacol (1999) 1.10
The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br J Clin Pharmacol (1979) 1.10
Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol (1978) 1.10
Plasma adrenaline and noradrenaline concentrations and dopamine-beta-hydroxylase activity in myocardial infarction with and without cardiogenic shock. Br Heart J (1979) 1.10
The effects of serum, lithium, ethacrynic acid, and a low external concentration of potassium on specific [3H]-ouabain binding to human lymphocytes after incubation for 3 days. Br J Clin Pharmacol (1986) 1.07
Neurochemical and electrophysiological studies on the functional significance of burst firing in serotonergic neurons. Neuroscience (2000) 1.06
The contrasting actions of TRH and cycloheximide in altering the effects of centrally acting drugs: evidence for the non-involvement of dopamine sensitive adenylate cyclase. Neuropharmacology (1976) 1.05
Tryptophan hydroxylation in brain. Biochem Biophys Res Commun (1964) 1.04
The metabolism of 14 C-labelled -methyldopa in normal and hypertensive human subjects. Biochem J (1972) 1.04
Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience (2000) 1.04
Antidopaminergic effects of dietary tyrosine depletion in healthy subjects and patients with manic illness. Br J Psychiatry (2001) 1.04
Evidence for the presence of a vasoactive substance (possibly involved in the aetiology of cerebral arterial spasm) in cerebrospinal fluid from patients with subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry (1976) 1.04
The biosynthesis of 5-hydroxytryptamine in brain. Biochem J (1967) 1.03
Altered distribution of digoxin in renal failure--a cause of digoxin toxicity? Br J Clin Pharmacol (1976) 1.03
Evidence for a repetitive (burst) firing pattern in a sub-population of 5-hydroxytryptamine neurons in the dorsal and median raphe nuclei of the rat. Neuroscience (1995) 1.03
In vivo evidence that 5-HT(2C) receptors inhibit 5-HT neuronal activity via a GABAergic mechanism. Br J Pharmacol (2006) 1.02
Inhibition of median and dorsal raphe neurones following administration of the selective serotonin reuptake inhibitor paroxetine. Naunyn Schmiedebergs Arch Pharmacol (1995) 1.01
Power of exclusion for parentage verification and probability of match for identity in American Kennel Club breeds using 17 canine microsatellite markers. Anim Genet (2004) 1.01
Biological mesh reconstruction of perineal wounds following enhanced abdominoperineal excision of rectum (APER). Int J Colorectal Dis (2011) 1.01
The carcinoid syndrome. Am J Cardiol (1968) 1.00
TRH potentiates behavioural changes following increased brain 5-hydroxytryptamine accumulation in rats. Nature (1974) 0.99
Nutrient balance in humans: effects of diet composition. Am J Clin Nutr (1991) 0.98
Tranylcypromine ('Parnate') overdose: measurement of tranylcypromine concentrations and MAO inhibitory activity and identification of amphetamines in plasma. Psychol Med (1979) 0.98
Changes in blood lipids during six days of overfeeding with medium or long chain triglycerides. J Lipid Res (1990) 0.98
Cation transport abnormalities in vivo in untreated essential hypertension. Clin Sci (Lond) (1986) 0.98
Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol (1999) 0.98
A method for the study of cation transport in vivo: effects of digoxin administration and of chronic renal failure on the disposition of an oral load of rubidium chloride. Clin Sci (Lond) (1984) 0.97
The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. Br J Clin Pharmacol (1981) 0.97
Somatostatin, gastrointestinal peptides, and the carcinoid syndrome. Gut (1981) 0.96
Changes in platelet alpha 2-adrenoceptor binding post partum: possible relation to maternity blues. Lancet (1983) 0.96
BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors. Neuropharmacology (1993) 0.96
Welfare aspects of vertebrate pest control and culling: ranking control techniques for humaneness. Rev Sci Tech (2014) 0.96
Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis. Life Sci (1991) 0.96
Monitoring digoxin therapy: II. Determinants of the apparent volume of distribution. Br J Clin Pharmacol (1977) 0.95
A study of attachment loss patterns in survivor teeth at 18 months, 36 months and 5 years in community-dwelling older adults. J Periodontal Res (1997) 0.95
Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694). Brain Res (1991) 0.95
In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anaesthetized rat using microdialysis: changes in relation to 5-hydroxytryptaminergic neuronal activity. J Neurochem (1989) 0.94
Evidence for an altered mode of action of the sodium-lithium countertransporter in vivo in patients with untreated essential hypertension. J Hypertens (1993) 0.94
Monitoring digoxin therapy. The use of plasma digoxin concentration measurements in the diagnosis of digoxin toxicity. Q J Med (1978) 0.94
Single and repeated administration of neuroleptic drugs to rats: effects on striatal dopamine-sensitive adenylate cyclase and locomotor activity produced by tranylcypromine and L-tryptophan or L-Dopa. Psychopharmacology (Berl) (1976) 0.93
Effect of oral contraceptives on platelet noradrenaline and5-hydroxytryptamine receptors and aggregation. Lancet (1979) 0.93
Evidence that genetic variation in 5-HT transporter expression is linked to changes in 5-HT2A receptor function. Neuropharmacology (2007) 0.93
Pharmacokinetics of cytosine arabinoside in patients with acute myeloid leukaemia. Br J Clin Pharmacol (1979) 0.93
Repeated electroconvulsive shock extends the duration of enhanced gene expression for BDNF in rat brain compared with a single administration. Brain Res Mol Brain Res (1998) 0.92